EconPapers    
Economics at your fingertips  
 

Regulation of T cell afferent lymphatic migration by targeting LTβR-mediated non-classical NFκB signaling

Wenji Piao, Yanbao Xiong, Konrad Famulski, C. Colin Brinkman, Lushen Li, Nicholas Toney, Chelsea Wagner, Vikas Saxena, Thomas Simon and Jonathan S. Bromberg ()
Additional contact information
Wenji Piao: University of Maryland School of Medicine
Yanbao Xiong: University of Maryland School of Medicine
Konrad Famulski: University of Alberta
C. Colin Brinkman: University of Maryland School of Medicine
Lushen Li: University of Maryland School of Medicine
Nicholas Toney: University of Maryland School of Medicine
Chelsea Wagner: University of Maryland School of Medicine
Vikas Saxena: University of Maryland School of Medicine
Thomas Simon: University of Maryland School of Medicine
Jonathan S. Bromberg: University of Maryland School of Medicine

Nature Communications, 2018, vol. 9, issue 1, 1-15

Abstract: Abstract Lymphotoxin-beta receptor (LTβR) signaling in lymphatic endothelial cells (LEC) regulates leukocyte afferent lymphatic transendothelial migration (TEM). The function of individual signaling pathways for different leukocyte subsets is currently unknown. Here, we show that LTβR signals predominantly via the constitutive and ligand-driven non-classical NIK pathway. Targeting LTβR-NIK by an LTβR-derived decoy peptide (nciLT) suppresses the production of chemokines CCL21 and CXCL12, and enhances the expression of classical NFκB-driven VCAM-1 and integrin β4 to retain T cells on LEC and precludes T cell and dendritic cell TEM. nciLT inhibits contact hypersensitivity (CHS) at both the sensitization and elicitation stages, likely by inhibiting leukocyte migration. By contrast, targeting LTβR-classical NFκB signaling during the elicitation and resolution stages attenuates CHS, possibly by promoting leukocyte egress. These findings demonstrate the importance of LTβR signaling in leukocyte migration and LEC and lymphatic vessel function, and show that antagonist peptides may serve as lead compounds for therapeutic applications.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-05412-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-05412-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-05412-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-05412-0